Literature DB >> 14505932

Mapping cross-clade HIV-1 vaccine epitopes using a bioinformatics approach.

Anne S De Groot1, Bill Jesdale, William Martin, Caitlin Saint Aubin, Hakima Sbai, Andrew Bosma, Judy Lieberman, Gail Skowron, Fadi Mansourati, Kenneth H Mayer.   

Abstract

UNLABELLED: The genomic variability of HIV viruses circulating in different regions of the world has impeded the development of a globally relevant HIV vaccine. Broadly conserved HIV-1 cytotoxic T cell (CTL) epitopes were identified by screening protein sequences in the Los Alamos National Laboratory (LANL) HIV sequence database with a sequence parsing and matching algorithm (Conservatrix). Putative HIV-1 CTL epitopes were selected from this list using the epitope prediction tool EpiMatrix.
METHODS: One hundred peptides representing putative HLA A*0201, HLA A*1101, HLA A*0301, and HLA B*07 ligands conserved in many isolates of HIV-1 were synthesized. Seventy-five HLA A*0201, HLA A*1101 and HLA B*07 peptides were incubated with transport associated protein (TAP)-deficient T2 cells transfected with the gene for the corresponding human HLA molecule (HLA A*0201, HLA A*1101, and HLA B*07). Binding and stabilization of peptide-HLA complexes on the surface of the T2 cells was measured by FACS. T cell responses to the entire set of 100 peptides (HLA A*0201, HLA A*1101, HLA A*0301, and HLA B*07) were measured in ELIspot assays using PBMC from healthy HIV-1 infected subjects who possessed a matching HLA allele.
RESULTS: Fifty-seven (76%) of the 75 peptides tested in binding studies, including all (three of three) of the control (published) ligands bound to the T2 cells expressing the corresponding MHC molecule. Forty-three of the 100 peptides (43%) including all (four of four) of the control (published) epitopes tested in ELIspot assays stimulated gamma-interferon release. Thirty-one of these 43 epitopes are novel, highly conserved HIV-1 epitopes. EpiMatrix predicted and assays confirmed MHC-restriction by more than one HLA allele for nine of the 43 novel epitopes; of these epitopes five were recognized in the context of MHC "supertypes" and four were promiscuous epitopes.
CONCLUSION: Epitopes identified using this approach were conserved in a broad range of HIV-1 sequences derived from isolates obtained in Latin America, Africa, Asia, the Pacific Islands, Europe and the US. The successful identification of cross-clade epitopes by this bioinformatics approach may accelerate the development of a globally relevant HIV-1 vaccine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14505932     DOI: 10.1016/s0264-410x(03)00390-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  26 in total

1.  Harnessing the power of genomics and immunoinformatics to produce improved vaccines.

Authors:  Leonard Moise; Leslie Cousens; Joanna Fueyo; Anne S De Groot
Journal:  Expert Opin Drug Discov       Date:  2010-12-01       Impact factor: 6.098

2.  MHC-BPS: MHC-binder prediction server for identifying peptides of flexible lengths from sequence-derived physicochemical properties.

Authors:  Juan Cui; Lian Yi Han; Hong Huang Lin; Zhi Qun Tang; Li Jiang; Zhi Wei Cao; Yu Zong Chen
Journal:  Immunogenetics       Date:  2006-07-11       Impact factor: 2.846

3.  Extensive HLA class I allele promiscuity among viral CTL epitopes.

Authors:  Nicole Frahm; Karina Yusim; Todd J Suscovich; Sharon Adams; John Sidney; Peter Hraber; Hannah S Hewitt; Caitlyn H Linde; Daniel G Kavanagh; Tonia Woodberry; Leah M Henry; Kellie Faircloth; Jennifer Listgarten; Carl Kadie; Nebojsa Jojic; Kaori Sango; Nancy V Brown; Eunice Pae; M Tauheed Zaman; Florian Bihl; Ashok Khatri; Mina John; Simon Mallal; Francesco M Marincola; Bruce D Walker; Alessandro Sette; David Heckerman; Bette T Korber; Christian Brander
Journal:  Eur J Immunol       Date:  2007-09       Impact factor: 5.532

4.  Identification of immunogenic HLA-B7 "Achilles' heel" epitopes within highly conserved regions of HIV.

Authors:  Anne S De Groot; Daniel S Rivera; Julie A McMurry; Soren Buus; William Martin
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 3.641

5.  Conservation of HIV-1 T cell epitopes across time and clades: validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine.

Authors:  Lauren Levitz; Ousmane A Koita; Kotou Sangare; Matthew T Ardito; Christine M Boyle; John Rozehnal; Karamoko Tounkara; Sounkalo M Dao; Youssouf Koné; Zoumana Koty; Soren Buus; Leonard Moise; William D Martin; Anne S De Groot
Journal:  Vaccine       Date:  2012-10-24       Impact factor: 3.641

6.  Generation of human MHC (HLA-A11/DR1) transgenic mice for vaccine evaluation.

Authors:  Yang Zeng; Tongtong Gao; Guangyu Zhao; Yuting Jiang; Yi Yang; Hong Yu; Zhihua Kou; Yuchun Lone; Shihui Sun; Yusen Zhou
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

7.  Structural Neuroimaging and Neuropsychologic Signatures in Children With Vertically Acquired HIV.

Authors:  Robert Paul; Wasana Prasitsuebsai; Neda Jahanshad; Thanyawee Puthanakit; Paul Thompson; Linda Aurpibul; Rawiwan Hansudewechakul; Pope Kosalaraksa; Suparat Kanjanavanit; Chaiwat Ngampiyaskul; Wicharn Luesomboon; Sukalaya Lerdlum; Mantana Pothisri; Pannee Visrutaratna; Victor Valcour; Talia M Nir; Arvin Saremi; Stephen Kerr; Jintanat Ananworanich
Journal:  Pediatr Infect Dis J       Date:  2018-07       Impact factor: 2.129

8.  Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation.

Authors:  Mark J Geels; Sheri A Dubey; Kiersten Anderson; Elly Baan; Margreet Bakker; Georgios Pollakis; William A Paxton; John W Shiver; Jaap Goudsmit
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

9.  Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral therapy.

Authors:  Carlum Shiu; Coleen K Cunningham; Thomas Greenough; Petronella Muresan; Victor Sanchez-Merino; Vincent Carey; J Brooks Jackson; Carrie Ziemniak; Lawrence Fox; Marvin Belzer; Stuart C Ray; Katherine Luzuriaga; Deborah Persaud
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

10.  Between-host evolution of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1: an approach based on phylogenetically independent comparisons.

Authors:  Helen Piontkivska; Austin L Hughes
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.